Compare KLA Corp. (KLAC) vs 10X Genomics Inc (TXG) Price & Performance

KLA Corporation (KLAC) trades at $195.89, down 0.48% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $223.88. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.05 exceeding the $1.00 estimate, and maintains robust profitability with a net income margin of 35.57%. Revenue growth is supported by a $12.57 billion backlog driven by AI and advanced packaging demand, as highlighted in recent news.

The stock presents a compelling growth opportunity given its leadership in semiconductor process control and positive analyst sentiment, but elevated valuation ratios like a P/E of 53.75 pose risks if growth slows. Competition with Applied Materials and ASML, along with cyclical semiconductor industry exposure, requires monitoring. Institutional ownership trends and insider sales, such as CEO Richard Wallace's September 2026 transaction, add layers to the investment case.

10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.

The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.